BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: O'Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 2013;72 Suppl 2:ii111-5. [PMID: 23532440 DOI: 10.1136/annrheumdis-2012-202576] [Cited by in Crossref: 222] [Cited by in F6Publishing: 208] [Article Influence: 24.7] [Reference Citation Analysis]
Number Citing Articles
1 Isomäki P, Junttila I, Vidqvist KL, Korpela M, Silvennoinen O. The activity of JAK-STAT pathways in rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin 6 levels. Rheumatology (Oxford) 2015;54:1103-13. [PMID: 25406356 DOI: 10.1093/rheumatology/keu430] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 7.0] [Reference Citation Analysis]
2 Chen M, Dai SM. A novel treatment for psoriatic arthritis: Janus kinase inhibitors. Chin Med J (Engl). 2020;133:959-967. [PMID: 32209886 DOI: 10.1097/cm9.0000000000000711] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
3 Schett G, Elewaut D, McInnes IB, Dayer JM, Neurath MF. How cytokine networks fuel inflammation: Toward a cytokine-based disease taxonomy. Nat Med. 2013;19:822-824. [PMID: 23836224 DOI: 10.1038/nm.3260] [Cited by in Crossref: 238] [Cited by in F6Publishing: 202] [Article Influence: 26.4] [Reference Citation Analysis]
4 Vartoukian SR, Tilakaratne WM, Seoudi N, Bombardieri M, Bergmeier L, Tappuni AR, Fortune F. Dysregulation of the suppressor of cytokine signalling 3-signal transducer and activator of transcription-3 pathway in the aetiopathogenesis of Sjögren's syndrome. Clin Exp Immunol 2014;177:618-29. [PMID: 24827536 DOI: 10.1111/cei.12377] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
5 Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, de Jong A, Harel S, DeStefano GM, Rothman L, Singh P, Petukhova L, Mackay-Wiggan J, Christiano AM, Clynes R. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 2014;20:1043-9. [PMID: 25129481 DOI: 10.1038/nm.3645] [Cited by in Crossref: 407] [Cited by in F6Publishing: 372] [Article Influence: 50.9] [Reference Citation Analysis]
6 Liu Y, Gibson SA, Benveniste EN, Qin H. Opportunities for Translation from the Bench: Therapeutic Intervention of the JAK/STAT Pathway in Neuroinflammatory Diseases. Crit Rev Immunol 2015;35:505-27. [PMID: 27279046 DOI: 10.1615/CritRevImmunol.2016015517] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
7 Vogel RM, Erez A, Altan-Bonnet G. Dichotomy of cellular inhibition by small-molecule inhibitors revealed by single-cell analysis. Nat Commun 2016;7:12428. [PMID: 27687249 DOI: 10.1038/ncomms12428] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
8 Wallner FK, Hultquist Hopkins M, Woodworth N, Lindvall Bark T, Olofsson P, Tilevik A. Correlation and cluster analysis of immunomodulatory drugs based on cytokine profiles. Pharmacol Res 2018;128:244-51. [PMID: 29079427 DOI: 10.1016/j.phrs.2017.10.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Robinson MF, Damjanov N, Stamenkovic B, Radunovic G, Kivitz A, Cox L, Manukyan Z, Banfield C, Saunders M, Chandra D, Vincent MS, Mancuso J, Peeva E, Beebe JS. Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate. Arthritis Rheumatol 2020;72:1621-31. [PMID: 32419304 DOI: 10.1002/art.41316] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
10 Bechman K, Yates M, Galloway JB. The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors. Pharmacol Res 2019;147:104392. [PMID: 31401212 DOI: 10.1016/j.phrs.2019.104392] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 10.3] [Reference Citation Analysis]
11 Mostafa N, Phan K, Lai B, Smith SD. Comparing quality of life outcomes of JAK inhibitors and biological treatments for atopic dermatitis: a systematic review and network meta-analysis. Expert Rev Clin Pharmacol 2021;14:1435-44. [PMID: 34410205 DOI: 10.1080/17512433.2021.1970529] [Reference Citation Analysis]
12 Taylor PC, Abdul Azeez M, Kiriakidis S. Filgotinib for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs 2017;26:1181-7. [PMID: 28838249 DOI: 10.1080/13543784.2017.1372422] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
13 Stukalov A, Girault V, Grass V, Karayel O, Bergant V, Urban C, Haas DA, Huang Y, Oubraham L, Wang A, Hamad MS, Piras A, Hansen FM, Tanzer MC, Paron I, Zinzula L, Engleitner T, Reinecke M, Lavacca TM, Ehmann R, Wölfel R, Jores J, Kuster B, Protzer U, Rad R, Ziebuhr J, Thiel V, Scaturro P, Mann M, Pichlmair A. Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV. Nature 2021;594:246-52. [PMID: 33845483 DOI: 10.1038/s41586-021-03493-4] [Cited by in Crossref: 42] [Cited by in F6Publishing: 47] [Article Influence: 42.0] [Reference Citation Analysis]
14 MacDonald KPA, Betts BC, Couriel D. Reprint of: Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 2018;24:S7-S14. [PMID: 29425517 DOI: 10.1016/j.bbmt.2017.12.788] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
15 Norman P. Evaluation of WO-2013040863, WO-2013041042 and WO-2013043962. Selective JAK1 inhibitors based on a 3-aminopyrazole-4-carboxamide scaffold. Expert Opinion on Therapeutic Patents 2013;24:231-7. [DOI: 10.1517/13543776.2014.859245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
16 Aymeric E, Bensignor E. A case of presumed autoimmune subepidermal blistering dermatosis treated with oclacitinib. Vet Dermatol 2017;28:512-e123. [DOI: 10.1111/vde.12458] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
17 Quick L, Young R, Henrich IC, Wang X, Asmann YW, Oliveira AM, Chou MM. Jak1-STAT3 Signals Are Essential Effectors of the USP6/TRE17 Oncogene in Tumorigenesis. Cancer Res 2016;76:5337-47. [PMID: 27440725 DOI: 10.1158/0008-5472.CAN-15-2391] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
18 Balogh EA, Bashyam AM, Ghamrawi RI, Feldman SR. Emerging systemic drugs in the treatment of plaque psoriasis. Expert Opin Emerg Drugs 2020;25:89-100. [PMID: 32192366 DOI: 10.1080/14728214.2020.1745773] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
19 Banfield C, Scaramozza M, Zhang W, Kieras E, Page KM, Fensome A, Vincent M, Dowty ME, Goteti K, Winkle PJ, Peeva E. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis. J Clin Pharmacol 2018;58:434-47. [PMID: 29266308 DOI: 10.1002/jcph.1046] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
20 Tanaka Y, Millson D, Iwata S, Nakayamada S. Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study. Rheumatology (Oxford) 2021;60:2884-95. [PMID: 33254235 DOI: 10.1093/rheumatology/keaa732] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Toyoshima J, Shibata M, Kaibara A, Kaneko Y, Izutsu H, Nishimura T. Population pharmacokinetic analysis of peficitinib in patients with rheumatoid arthritis. Br J Clin Pharmacol 2021;87:2014-22. [PMID: 33068028 DOI: 10.1111/bcp.14605] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
22 Ciechanowicz P, Rakowska A, Sikora M, Rudnicka L. JAK-inhibitors in dermatology: current evidence and future applications. Journal of Dermatological Treatment 2019;30:648-58. [DOI: 10.1080/09546634.2018.1546043] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
23 Dai Z, Chen J, Chang Y, Christiano AM. Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata. JCI Insight 2021;6:142205. [PMID: 33830087 DOI: 10.1172/jci.insight.142205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Brosius FC 3rd, He JC. JAK inhibition and progressive kidney disease. Curr Opin Nephrol Hypertens 2015;24:88-95. [PMID: 25415616 DOI: 10.1097/MNH.0000000000000079] [Cited by in Crossref: 56] [Cited by in F6Publishing: 32] [Article Influence: 8.0] [Reference Citation Analysis]
25 Hatami M, Salmani T, Arsang-jang S, Davood Omrani M, Mazdeh M, Ghafouri-fard S, Sayad A, Taheri M. STAT5a and STAT6 gene expression levels in multiple sclerosis patients. Cytokine 2018;106:108-13. [DOI: 10.1016/j.cyto.2017.10.022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
26 Fleischmann RM, Damjanov NS, Kivitz AJ, Legedza A, Hoock T, Kinnman N. A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis. Arthritis Rheumatol 2015;67:334-43. [PMID: 25385260 DOI: 10.1002/art.38949] [Cited by in Crossref: 76] [Cited by in F6Publishing: 61] [Article Influence: 10.9] [Reference Citation Analysis]
27 Deviatkin AA, Vakulenko YA, Akhmadishina LV, Tarasov VV, Beloukhova MI, Zamyatnin AA Jr, Lukashev AN. Emerging Concepts and Challenges in Rheumatoid Arthritis Gene Therapy. Biomedicines 2020;8:E9. [PMID: 31936504 DOI: 10.3390/biomedicines8010009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
28 Behin A, Le Panse R. New Pathways and Therapeutic Targets in Autoimmune Myasthenia Gravis. J Neuromuscul Dis 2018;5:265-77. [PMID: 30010142 DOI: 10.3233/JND-170294] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 4.8] [Reference Citation Analysis]
29 Heo MJ, Lee C, Choi SY, Choi YM, An IS, Bae S, An S, Jung JH. Nintedanib ameliorates animal model of dermatitis. Sci Rep 2020;10:4493. [PMID: 32161331 DOI: 10.1038/s41598-020-61424-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Wang EHC, Sallee BN, Tejeda CI, Christiano AM. JAK Inhibitors for Treatment of Alopecia Areata. J Invest Dermatol 2018;138:1911-6. [PMID: 30057345 DOI: 10.1016/j.jid.2018.05.027] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
31 Fitzpatrick LR. Inhibition of IL-17 as a pharmacological approach for IBD. Int Rev Immunol. 2013;32:544-555. [PMID: 23886112 DOI: 10.3109/08830185.2013.821118] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
32 Markovics A, Rosenthal KS, Mikecz K, Carambula RE, Ciemielewski JC, Zimmerman DH. Restoring the Balance between Pro-Inflammatory and Anti-Inflammatory Cytokines in the Treatment of Rheumatoid Arthritis: New Insights from Animal Models. Biomedicines 2022;10:44. [DOI: 10.3390/biomedicines10010044] [Reference Citation Analysis]
33 Namour F, Fagard L, Van der Aa A, Harrison P, Xin Y, Tasset C. Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor. Br J Clin Pharmacol 2018;84:2779-89. [PMID: 30088677 DOI: 10.1111/bcp.13726] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
34 Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, Zhu L, Papacharalambous J, Vincent MS, Peeva E. Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial. JAMA Dermatol 2019;155:1371-9. [PMID: 31577341 DOI: 10.1001/jamadermatol.2019.2855] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 31.5] [Reference Citation Analysis]
35 Louis C, Ngo D, D'silva DB, Hansen J, Phillipson L, Jousset H, Novello P, Segal D, Lawlor KE, Burns CJ, Wicks IP. Therapeutic Effects of a TANK ‐Binding Kinase 1 Inhibitor in Germinal Center–Driven Collagen‐Induced Arthritis. Arthritis Rheumatol 2018;71:50-62. [DOI: 10.1002/art.40670] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
36 Kremer JM, Emery P, Camp HS, Friedman A, Wang L, Othman AA, Khan N, Pangan AL, Jungerwirth S, Keystone EC. A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy. Arthritis Rheumatol. 2016;68:2867-2877. [PMID: 27389975 DOI: 10.1002/art.39801] [Cited by in Crossref: 106] [Cited by in F6Publishing: 97] [Article Influence: 21.2] [Reference Citation Analysis]
37 Alrabiah H, Kadi AA, Attwa MW, Mostafa GA. Development and validation of an HPLC-MS/MS method for the determination of filgotinib, a selective Janus kinase 1 inhibitor: Application to a metabolic stability study. Journal of Chromatography B 2020;1154:122195. [DOI: 10.1016/j.jchromb.2020.122195] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
38 Ladhari C, Jorgensen C, Pers YM. Treatment of refractory adult onset Still's disease with combination anakinra and baricitinib therapy. Rheumatology (Oxford) 2019;58:736-7. [PMID: 30590753 DOI: 10.1093/rheumatology/key414] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
39 Galvez-Llompart M, Ocello R, Rullo L, Stamatakos S, Alessandrini I, Zanni R, Tuñón I, Cavalli A, Candeletti S, Masetti M, Romualdi P, Recanatini M. Targeting the JAK/STAT Pathway: A Combined Ligand- and Target-Based Approach. J Chem Inf Model 2021;61:3091-108. [PMID: 33998810 DOI: 10.1021/acs.jcim.0c01468] [Reference Citation Analysis]
40 [DOI: 10.1101/2020.06.17.156455] [Cited by in Crossref: 72] [Cited by in F6Publishing: 26] [Reference Citation Analysis]
41 Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs. 2017;77:521-546. [PMID: 28255960 DOI: 10.1007/s40265-017-0701-9] [Cited by in Crossref: 259] [Cited by in F6Publishing: 256] [Article Influence: 51.8] [Reference Citation Analysis]
42 Malergue F, van Agthoven A, Scifo C, Egan D, Strous GJ. Automation of a Phospho-STAT5 Staining Procedure for Flow Cytometry for Application in Drug Discovery. J Biomol Screen 2015;20:416-21. [DOI: 10.1177/1087057114555477] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
43 Triyangkulsri K, Suchonwanit P. Role of janus kinase inhibitors in the treatment of alopecia areata. Drug Des Devel Ther 2018;12:2323-35. [PMID: 30100707 DOI: 10.2147/DDDT.S172638] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
44 Shibata M, Toyoshima J, Kaneko Y, Oda K, Nishimura T. A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers. Eur J Clin Pharmacol 2020;76:1135-41. [PMID: 32472157 DOI: 10.1007/s00228-020-02876-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
45 Tanaka Y. Current concepts in the management of rheumatoid arthritis. Korean J Intern Med 2016;31:210-8. [PMID: 26932398 DOI: 10.3904/kjim.2015.137] [Cited by in Crossref: 47] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]
46 Tanaka Y, Emoto K, Cai Z, Aoki T, Schlichting D, Rooney T, Macias W. Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study. J Rheumatol 2016;43:504-11. [PMID: 26834213 DOI: 10.3899/jrheum.150613] [Cited by in Crossref: 82] [Cited by in F6Publishing: 78] [Article Influence: 13.7] [Reference Citation Analysis]
47 Genovese MC, Smolen JS, Weinblatt ME, Burmester GR, Meerwein S, Camp HS, Wang L, Othman AA, Khan N, Pangan AL, Jungerwirth S. Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. Arthritis Rheumatol 2016;68:2857-66. [PMID: 27390150 DOI: 10.1002/art.39808] [Cited by in Crossref: 123] [Cited by in F6Publishing: 107] [Article Influence: 24.6] [Reference Citation Analysis]
48 Witte S, Muljo SA. Integrating non-coding RNAs in JAK-STAT regulatory networks. JAKSTAT 2014;3:e28055. [PMID: 24778925 DOI: 10.4161/jkst.28055] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
49 Tanaka Y. A review of upadacitinib in rheumatoid arthritis. Modern Rheumatology 2020;30:779-87. [DOI: 10.1080/14397595.2020.1782049] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
50 Zhu T, Moy S, Valluri U, Cao Y, Zhang W, Sawamoto T, Chindalore V, Akinlade B. Investigation of Potential Drug-Drug Interactions between Peficitinib (ASP015K) and Methotrexate in Patients with Rheumatoid Arthritis. Clin Drug Investig 2020;40:827-38. [PMID: 32591978 DOI: 10.1007/s40261-020-00937-z] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Kameda H, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Yokoyama M, Pangan AL, Konishi Y, Meerwein S, Tanaka Y. Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE). Arthritis Res Ther 2021;23:9. [PMID: 33407801 DOI: 10.1186/s13075-020-02387-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Soh HJ, Samuel C, Heaton V, Renton WD, Cox A, Munro J. Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review. Rheumatol Int 2019;39:933-41. [DOI: 10.1007/s00296-019-04269-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
53 Srivastava SB, Fluegel N, Mansukhani RP. Pharmacologic Management of Rheumatoid Arthritis. Orthop Nurs 2019;38:390-5. [PMID: 31764904 DOI: 10.1097/NOR.0000000000000610] [Reference Citation Analysis]
54 Mikhaylov D, Pavel A, Yao C, Kimmel G, Nia J, Hashim P, Vekaria AS, Taliercio M, Singer G, Karalekas R, Baum D, Mansouri Y, Lebwohl MG, Guttman-Yassky E. A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata. Arch Dermatol Res 2019;311:29-36. [PMID: 30417279 DOI: 10.1007/s00403-018-1876-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
55 Bechman K, Galloway JB, Winthrop KL. Small-Molecule Protein Kinases Inhibitors and the Risk of Fungal Infections. Curr Fungal Infect Rep 2019;13:229-43. [DOI: 10.1007/s12281-019-00350-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
56 Shaheryar ZA, Khan MA, Adnan CS, Zaidi AA, Hänggi D, Muhammad S. Neuroinflammatory Triangle Presenting Novel Pharmacological Targets for Ischemic Brain Injury. Front Immunol 2021;12:748663. [PMID: 34691061 DOI: 10.3389/fimmu.2021.748663] [Reference Citation Analysis]
57 Comen EA, Bowman RL, Kleppe M. Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment. Front Cell Dev Biol 2018;6:56. [PMID: 29946544 DOI: 10.3389/fcell.2018.00056] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
58 Fowler DH. Rapamycin-resistant effector T-cell therapy. Immunol Rev 2014;257:210-25. [PMID: 24329799 DOI: 10.1111/imr.12127] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
59 Kettle JG, Åstrand A, Catley M, Grimster NP, Nilsson M, Su Q, Woessner R. Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2. Expert Opin Ther Pat 2017;27:145-61. [PMID: 27774822 DOI: 10.1080/13543776.2017.1252754] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
60 Napolitano M, Marasca C, Fabbrocini G, Patruno C. Adult atopic dermatitis: new and emerging therapies. Expert Rev Clin Pharmacol 2018;11:867-78. [PMID: 30073901 DOI: 10.1080/17512433.2018.1507734] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
61 Cotter DG, Schairer D, Eichenfield L. Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol 2018;78:S53-62. [PMID: 29248518 DOI: 10.1016/j.jaad.2017.12.019] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 10.6] [Reference Citation Analysis]
62 Wiegertjes R, van de Loo FAJ, Blaney Davidson EN. A roadmap to target interleukin-6 in osteoarthritis. Rheumatology (Oxford) 2020;59:2681-94. [PMID: 32691066 DOI: 10.1093/rheumatology/keaa248] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
63 Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, Beattie S, Witt S, de la Torre I, Gaich C, Rooney T, Schlichting D, de Bono S, Emery P. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 2017;76:88-95. [PMID: 27689735 DOI: 10.1136/annrheumdis-2016-210094] [Cited by in Crossref: 187] [Cited by in F6Publishing: 170] [Article Influence: 31.2] [Reference Citation Analysis]
64 Mohamed MF, Klünder B, Camp HS, Othman AA. Exposure-Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection. Clin Pharmacol Ther 2019;106:1319-27. [PMID: 31194885 DOI: 10.1002/cpt.1543] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
65 Kawalec P, Śladowska K, Malinowska-Lipień I, Brzostek T, Kózka M. New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib. Ther Clin Risk Manag 2019;15:275-84. [PMID: 30858707 DOI: 10.2147/TCRM.S192440] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
66 Morris G, Bortolasci CC, Puri BK, Marx W, O'Neil A, Athan E, Walder K, Berk M, Olive L, Carvalho AF, Maes M. The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all? Cytokine 2021;144:155593. [PMID: 34074585 DOI: 10.1016/j.cyto.2021.155593] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
67 Babu S, Nagarajan SK, Madhavan T. Investigation of Empirical and Semi‐Empirical Charges to Study the Effects of Partial Charges on Quality and Prediction Accuracy in 3D‐QSAR. ChemistrySelect 2019;4:3990-4002. [DOI: 10.1002/slct.201803387] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
68 Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG. Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context 2019;8:212595. [PMID: 31692920 DOI: 10.7573/dic.212595] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
69 Ferreira S, Guttman-Yassky E, Torres T. Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib. Am J Clin Dermatol 2020;21:783-98. [PMID: 32776305 DOI: 10.1007/s40257-020-00548-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
70 Chou DH, Vetere A, Choudhary A, Scully SS, Schenone M, Tang A, Gomez R, Burns SM, Lundh M, Vital T, Comer E, Faloon PW, Dančík V, Ciarlo C, Paulk J, Dai M, Reddy C, Sun H, Young M, Donato N, Jaffe J, Clemons PA, Palmer M, Carr SA, Schreiber SL, Wagner BK. Kinase-Independent Small-Molecule Inhibition of JAK-STAT Signaling. J Am Chem Soc 2015;137:7929-34. [PMID: 26042473 DOI: 10.1021/jacs.5b04284] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
71 De Vries LCS, Wildenberg ME, De Jonge WJ, D'Haens GR. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease. J Crohns Colitis 2017;11:885-93. [PMID: 28158411 DOI: 10.1093/ecco-jcc/jjx003] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 12.5] [Reference Citation Analysis]
72 Gundacker ND, Baddley JW. Fungal Infections in the Era of Biologic Therapies. Curr Clin Micro Rpt 2015;2:76-83. [DOI: 10.1007/s40588-015-0018-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
73 Castañeda S, García-castañeda N, Prieto-peña D, Martínez-quintanilla D, Vicente EF, Blanco R, González-gay MA. Treatment of polymyalgia rheumatica. Biochemical Pharmacology 2019;165:221-9. [DOI: 10.1016/j.bcp.2019.03.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
74 Lin CM, Cooles FA, Isaacs JD. Basic Mechanisms of JAK Inhibition. Mediterr J Rheumatol 2020;31:100-4. [PMID: 32676567 DOI: 10.31138/mjr.31.1.100] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
75 da Mota LM, Cruz BA, de Albuquerque CP, Gonçalves DP, Laurindo IM, Pereira IA, de Carvalho JF, Pinheiro Gda R, Bertolo MB, Pinto MR, Louzada-Junior P, Xavier RM, Giorgi RD, Lima RA. Update on the 2012 Brazilian Society of Rheumatology Guidelines for the treatment of rheumatoid arthritis: position on the use of tofacitinib. Rev Bras Reumatol 2015;55:512-21. [PMID: 26456224 DOI: 10.1016/j.rbr.2015.08.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
76 Tanaka Y, Takeuchi T, Tanaka S, Kawakami A, Iwasaki M, Song YW, Chen YH, Wei JC, Lee SH, Rokuda M, Izutsu H, Ushijima S, Kaneko Y, Akazawa R, Shiomi T, Yamada E. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). Ann Rheum Dis. 2019;78:1320-1332. [PMID: 31350270 DOI: 10.1136/annrheumdis-2019-215163] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 16.0] [Reference Citation Analysis]
77 Thompson C, Davies R, Choy E. Anti cytokine therapy in chronic inflammatory arthritis. Cytokine 2016;86:92-9. [DOI: 10.1016/j.cyto.2016.07.015] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
78 Williams HD, Ford L, Han S, Tangso KJ, Lim S, Shackleford DM, Vodak DT, Benameur H, Pouton CW, Scammells PJ, Porter CJH. Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid-Based Formulations. Mol Pharm 2018;15:5678-96. [PMID: 30376336 DOI: 10.1021/acs.molpharmaceut.8b00858] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
79 Matossian C, McDonald M, Donaldson KE, Nichols KK, MacIver S, Gupta PK. Dry Eye Disease: Consideration for Women's Health. J Womens Health (Larchmt) 2019;28:502-14. [PMID: 30694724 DOI: 10.1089/jwh.2018.7041] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
80 Genovese MC, Greenwald M, Codding C, Zubrzycka‐sienkiewicz A, Kivitz AJ, Wang A, Shay K, Wang X, Garg JP, Cardiel MH. Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease‐Modifying Antirheumatic Drugs in the Treatment of Moderate‐to‐Severe Rheumatoid Arthritis. Arthritis & Rheumatology 2017;69:932-42. [DOI: 10.1002/art.40054] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 11.8] [Reference Citation Analysis]
81 Kremer JM, Genovese MC, Keystone E, Taylor PC, Zuckerman SH, Ruotolo G, Schlichting DE, Crotzer VL, Nantz E, Beattie SD, Macias WL. Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis. Arthritis & Rheumatology 2017;69:943-52. [DOI: 10.1002/art.40036] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
82 Alten R. Intrazelluläre Targets: Aktuelle Datenlage zu Wirksamkeit und Sicherheitsprofil. Z Rheumatol 2013;72:867-72. [DOI: 10.1007/s00393-013-1139-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
83 An Q, Yan W, Zhao Y, Yu K. Enhanced neutrophil autophagy and increased concentrations of IL-6, IL-8, IL-10 and MCP-1 in rheumatoid arthritis. Int Immunopharmacol 2018;65:119-28. [PMID: 30312880 DOI: 10.1016/j.intimp.2018.09.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
84 Veale DJ, McGonagle D, McInnes IB, Krueger JG, Ritchlin CT, Elewaut D, Kanik KS, Hendrikx T, Berstein G, Hodge J, Telliez JB. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. Rheumatology (Oxford) 2019;58:197-205. [PMID: 29618084 DOI: 10.1093/rheumatology/key070] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
85 Toussirot E. The Use of Janus Kinase Inhibitors in Axial Spondyloarthritis: Current Insights. Pharmaceuticals 2022;15:270. [DOI: 10.3390/ph15030270] [Reference Citation Analysis]
86 Abdo AIK, Tye GJ. Interleukin 23 and autoimmune diseases: current and possible future therapies. Inflamm Res 2020;69:463-80. [PMID: 32215665 DOI: 10.1007/s00011-020-01339-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
87 Kleppe M, Spitzer MH, Li S, Hill CE, Dong L, Papalexi E, De Groote S, Bowman RL, Keller M, Koppikar P, Rapaport FT, Teruya-Feldstein J, Gandara J, Mason CE, Nolan GP, Levine RL. Jak1 Integrates Cytokine Sensing to Regulate Hematopoietic Stem Cell Function and Stress Hematopoiesis. Cell Stem Cell 2017; 21: 489-501. e7. [PMID: 28965767 DOI: 10.1016/j.stem.2017.08.011] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
88 Goedken ER, Argiriadi MA, Banach DL, Fiamengo BA, Foley SE, Frank KE, George JS, Harris CM, Hobson AD, Ihle DC, Marcotte D, Merta PJ, Michalak ME, Murdock SE, Tomlinson MJ, Voss JW. Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol. J Biol Chem 2015;290:4573-89. [PMID: 25552479 DOI: 10.1074/jbc.M114.595181] [Cited by in Crossref: 59] [Cited by in F6Publishing: 20] [Article Influence: 7.4] [Reference Citation Analysis]
89 Cavalli G, Farina N, Campochiaro C, De Luca G, Della-Torre E, Tomelleri A, Dagna L. Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. Front Pharmacol 2020;11:598308. [PMID: 33442386 DOI: 10.3389/fphar.2020.598308] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
90 Toyoshima J, Kaibara A, Shibata M, Kaneko Y, Izutsu H, Nishimura T. Exposure-response modeling of peficitinib efficacy in patients with rheumatoid arthritis. Pharmacol Res Perspect 2021;9:e00744. [PMID: 33929089 DOI: 10.1002/prp2.744] [Reference Citation Analysis]
91 Tanaka Y, Izutsu H. Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials. Expert Opin Pharmacother 2020;21:1015-25. [PMID: 32345068 DOI: 10.1080/14656566.2020.1739649] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
92 Wittine K, Antolović R, Jelić D, Bracanović S, Cetina M, Andjelkovic U, Wittine O, Kraljević Pavelić S, Vinter A. Thienochromene derivatives inhibit pSTAT1 and pSTAT5 signaling induced by cytokines. Bioorg Med Chem Lett 2020;30:127415. [PMID: 32717616 DOI: 10.1016/j.bmcl.2020.127415] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
93 Babu S, Nagarajan SK, Madhavan T. Understanding the structural features of JAK2 inhibitors: a combined 3D-QSAR, DFT and molecular dynamics study. Mol Divers 2019;23:845-74. [PMID: 30617940 DOI: 10.1007/s11030-018-09913-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
94 Iyer AK, Liu J, Gallo RM, Kaplan MH, Brutkiewicz RR. STAT3 promotes CD1d-mediated lipid antigen presentation by regulating a critical gene in glycosphingolipid biosynthesis. Immunology 2015;146:444-55. [PMID: 26260288 DOI: 10.1111/imm.12521] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
95 Bisiaux A, Boussier J, Duffy D, Quintana-Murci L, Fontes M, Albert ML; Milieu Intérieur Consortium. Deconvolution of the Response to Bacillus Calmette-Guérin Reveals NF-κB-Induced Cytokines As Autocrine Mediators of Innate Immunity. Front Immunol 2017;8:796. [PMID: 28751891 DOI: 10.3389/fimmu.2017.00796] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
96 Amrhein J, Drynda S, Schlatt L, Karst U, Lohmann CH, Ciarimboli G, Bertrand J. Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA. Int J Mol Sci 2020;21:E6632. [PMID: 32927842 DOI: 10.3390/ijms21186632] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
97 Garbers C, Heink S, Korn T, Rose-John S. Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov. 2018;17:395-412. [PMID: 29725131 DOI: 10.1038/nrd.2018.45] [Cited by in Crossref: 209] [Cited by in F6Publishing: 197] [Article Influence: 52.3] [Reference Citation Analysis]
98 Salgado E, Maneiro JR. [New therapies for rheumatoid arthritis]. Med Clin (Barc) 2014;143:461-6. [PMID: 24461738 DOI: 10.1016/j.medcli.2013.11.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
99 Koizumi H, Arito M, Endo W, Kurokawa MS, Okamoto K, Omoteyama K, Suematsu N, Beppu M, Kato T. Effects of tofacitinib on nucleic acid metabolism in human articular chondrocytes. Mod Rheumatol 2015;25:522-7. [PMID: 25496463 DOI: 10.3109/14397595.2014.995874] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
100 Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford) 2019;58:i43-54. [PMID: 30806709 DOI: 10.1093/rheumatology/key276] [Cited by in Crossref: 92] [Cited by in F6Publishing: 93] [Article Influence: 46.0] [Reference Citation Analysis]
101 Jones P, Storer RI, Sabnis YA, Wakenhut FM, Whitlock GA, England KS, Mukaiyama T, Dehnhardt CM, Coe JW, Kortum SW, Chrencik JE, Brown DG, Jones RM, Murphy JR, Yeoh T, Morgan P, Kilty I. Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin. J Med Chem 2017;60:767-86. [DOI: 10.1021/acs.jmedchem.6b01634] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
102 MacDonald KPA, Betts BC, Couriel D. Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 2018;24:19-26. [PMID: 29032060 DOI: 10.1016/j.bbmt.2017.10.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
103 Mina-Osorio P. Review: basics of drug development in rheumatology. Arthritis Rheumatol 2015;67:2581-90. [PMID: 26138901 DOI: 10.1002/art.39253] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
104 Rachubinski AL, Estrada BE, Norris D, Dunnick CA, Boldrick JC, Espinosa JM. Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata. JAAD Case Rep 2019;5:365-7. [PMID: 31008170 DOI: 10.1016/j.jdcr.2019.02.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
105 Benveniste EN, Liu Y, McFarland BC, Qin H. Involvement of the janus kinase/signal transducer and activator of transcription signaling pathway in multiple sclerosis and the animal model of experimental autoimmune encephalomyelitis. J Interferon Cytokine Res 2014;34:577-88. [PMID: 25084174 DOI: 10.1089/jir.2014.0012] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 6.6] [Reference Citation Analysis]
106 Zhang X, Chua L, Ernest C 2nd, Macias W, Rooney T, Tham LS. Dose/Exposure-Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis. CPT Pharmacometrics Syst Pharmacol 2017;6:804-13. [PMID: 28891251 DOI: 10.1002/psp4.12251] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
107 Tektonidou MG. JAK inhibitors: promising for a wider spectrum of autoimmune diseases? Lancet 2019;394:2047-8. [PMID: 31732181 DOI: 10.1016/S0140-6736(19)32681-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
108 Dixit A, Kiran V, Gabani BB, Mohd Z, Trivedi RK, Mullangi R. Validated LC–MS/MS method for quantitation of a selective JAK1 inhibitor, filgotinib in rat plasma, and its application to a pharmacokinetic study in rats. Biomedical Chromatography 2020;34. [DOI: 10.1002/bmc.4802] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Srinivas NR. Comment on: "Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modelling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection". Clin Pharmacokinet 2015;54:1293-5. [PMID: 26482169 DOI: 10.1007/s40262-015-0335-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
110 Peeva E, Hodge MR, Kieras E, Vazquez ML, Goteti K, Tarabar SG, Alvey CW, Banfield C. Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study. Br J Clin Pharmacol 2018;84:1776-88. [PMID: 29672897 DOI: 10.1111/bcp.13612] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
111 Perner F, Perner C, Ernst T, Heidel FH. Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation. Cells 2019;8:E854. [PMID: 31398915 DOI: 10.3390/cells8080854] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 17.0] [Reference Citation Analysis]
112 Yamaguchi R, Perkins G. Animal models for studying tumor microenvironment (TME) and resistance to lymphocytic infiltration. Cancer Biol Ther 2018;19:745-54. [PMID: 29723108 DOI: 10.1080/15384047.2018.1470722] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
113 Raimondo MG, Biggioggero M, Coletto LA, Ramming A, Caporali R, Favalli EG. Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights. Expert Rev Clin Pharmacol 2021;14:661-70. [PMID: 33847204 DOI: 10.1080/17512433.2021.1913050] [Reference Citation Analysis]
114 Tanaka Y. Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside. J Biochem 2015;158:173-9. [DOI: 10.1093/jb/mvv069] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 7.1] [Reference Citation Analysis]
115 Almohanna HM, Perper M, Tosti A. Safety concerns when using novel medications to treat alopecia. Expert Opin Drug Saf 2018;17:1115-28. [PMID: 30318935 DOI: 10.1080/14740338.2018.1533549] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
116 Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, Lee CH, Fidelus-Gort RK, Luchi ME, Rooney TP, Macias WL, Genovese MC. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis 2015;74:333-40. [PMID: 25431052 DOI: 10.1136/annrheumdis-2014-206478] [Cited by in Crossref: 167] [Cited by in F6Publishing: 146] [Article Influence: 20.9] [Reference Citation Analysis]
117 Hosseini A, Gharibi T, Mohammadzadeh A, Ebrahimi-Kalan A, Jadidi-Niaragh F, Babaloo Z, Shanehbandi D, Baghbani E, Baradaran B. Ruxolitinib attenuates experimental autoimmune encephalomyelitis (EAE) development as animal models of multiple sclerosis (MS). Life Sci 2021;276:119395. [PMID: 33781828 DOI: 10.1016/j.lfs.2021.119395] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Elmongy EI, Henidi HA. In Silico Evaluation of a Promising Key Intermediate Thieno [2,3-d] Pyrimidine Derivative with Expected JAK2 Kinase Inhibitory Activity. Molbank 2022;2022:M1352. [DOI: 10.3390/m1352] [Reference Citation Analysis]
119 Bauer SM, Gehringer M, Laufer SA. A direct enzyme-linked immunosorbent assay (ELISA) for the quantitative evaluation of Janus Kinase 3 (JAK3) inhibitors. Anal Methods 2014;6:8817-22. [DOI: 10.1039/c4ay01589d] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
120 Kim HO. Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors. Arch Pharm Res 2020;43:1173-86. [PMID: 33161563 DOI: 10.1007/s12272-020-01282-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
121 Alajlan AM, AlZamil LR, Aseri AM. Tofacitinib Treatment in Patients With Active COVID-19 Infection. Cureus 2021;13:e17957. [PMID: 34660145 DOI: 10.7759/cureus.17957] [Reference Citation Analysis]
122 Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis 2021;80:865-75. [PMID: 33741556 DOI: 10.1136/annrheumdis-2020-219012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
123 Tanaka Y, Matsubara T, Atsumi T, Amano K, Ishiguro N, Sugiyama E, Yamaoka K, Combe BG, Kivitz AJ, Bae SC, Keystone EC, Nash P, Matzkies F, Bartok B, Pechonkina A, Kondo A, Ye L, Guo Y, Tasset C, Sundy JS, Takeuchi T. Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1). Mod Rheumatol 2021:roab030. [PMID: 34910188 DOI: 10.1093/mr/roab030] [Reference Citation Analysis]
124 Li H, Tsokos GC. IL-23/IL-17 Axis in Inflammatory Rheumatic Diseases. Clin Rev Allergy Immunol 2021;60:31-45. [PMID: 33185790 DOI: 10.1007/s12016-020-08823-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Godfrey MS, Friedman LN. Tuberculosis and Biologic Therapies: Anti-Tumor Necrosis Factor-α and Beyond. Clin Chest Med 2019;40:721-39. [PMID: 31731980 DOI: 10.1016/j.ccm.2019.07.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
126 Garbers C, Scheller J. Interleukin-6 and interleukin-11: same same but different. Biol Chem 2013;394:1145-61. [PMID: 23740659 DOI: 10.1515/hsz-2013-0166] [Cited by in Crossref: 80] [Cited by in F6Publishing: 77] [Article Influence: 10.0] [Reference Citation Analysis]
127 Wang L, Xian YF, Loo SKF, Ip SP, Yang W, Chan WY, Lin ZX, Wu JCY. Baicalin ameliorates 2,4-dinitrochlorobenzene-induced atopic dermatitis-like skin lesions in mice through modulating skin barrier function, gut microbiota and JAK/STAT pathway. Bioorg Chem 2021;119:105538. [PMID: 34929516 DOI: 10.1016/j.bioorg.2021.105538] [Reference Citation Analysis]
128 Ito M, Yamazaki S, Yamagami K, Kuno M, Morita Y, Okuma K, Nakamura K, Chida N, Inami M, Inoue T, Shirakami S, Higashi Y. A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model. J Pharmacol Sci 2017;133:25-33. [PMID: 28117214 DOI: 10.1016/j.jphs.2016.12.001] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 7.7] [Reference Citation Analysis]
129 García-Bermúdez M, López-Mejías R, Genre F, Castañeda S, Corrales A, Llorca J, González-Juanatey C, Ubilla B, Miranda-Filloy JA, Pina T, Gómez-Vaquero C, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Balsa A, Pascual-Salcedo D, López-Longo FJ, Carreira P, Blanco R, Martín J, González-Gay MA. Lack of association between JAK3 gene polymorphisms and cardiovascular disease in Spanish patients with rheumatoid arthritis. Biomed Res Int 2015;2015:318364. [PMID: 25815310 DOI: 10.1155/2015/318364] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
130 Gordon SC, Trudeau S, Regev A, Uhas JM, Chakladar S, Pinto-Correia A, Gottlieb K, Schlichting D. Baricitinib and primary biliary cholangitis. J Transl Autoimmun 2021;4:100107. [PMID: 34195587 DOI: 10.1016/j.jtauto.2021.100107] [Reference Citation Analysis]
131 Tanaka Y, Luo Y, O'Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol 2022. [PMID: 34987201 DOI: 10.1038/s41584-021-00726-8] [Reference Citation Analysis]
132 Gazitt T, Zisman D, Gardner G. Polymyalgia Rheumatica: a Common Disease in Seniors. Curr Rheumatol Rep 2020;22:40. [PMID: 32562020 DOI: 10.1007/s11926-020-00919-2] [Reference Citation Analysis]
133 Shao BY, Zhang SF, Li HD, Meng XM, Chen HY. Epigenetics and Inflammation in Diabetic Nephropathy. Front Physiol 2021;12:649587. [PMID: 34025445 DOI: 10.3389/fphys.2021.649587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
134 Jones SA, Takeuchi T, Aletaha D, Smolen J, Choy EH, Mcinnes I. Interleukin 6: The biology behind the therapy. Considerations Med 2019;2:2-6. [DOI: 10.1136/conmed-2018-000005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
135 Pringle S, Wang X, Bootsma H, Spijkervet FKL, Vissink A, Kroese FGM. Small-molecule inhibitors and the salivary gland epithelium in Sjögren's syndrome. Expert Opin Investig Drugs 2019;28:605-16. [PMID: 31203680 DOI: 10.1080/13543784.2019.1631796] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
136 Rapalli VK, Singhvi G, Dubey SK, Gupta G, Chellappan DK, Dua K. Emerging landscape in psoriasis management: From topical application to targeting biomolecules. Biomedicine & Pharmacotherapy 2018;106:707-13. [DOI: 10.1016/j.biopha.2018.06.136] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 8.8] [Reference Citation Analysis]
137 Zhang Y, Xu C, Liu T, Zhu Y, Luo Y. An improved synthesis of 4-chloro-7H-pyrrolo[2,3-d]pyrimidine. Chem Heterocycl Comp 2018;54:638-42. [DOI: 10.1007/s10593-018-2320-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Rodrigues MA, Torres T. JAK/STAT inhibitors for the treatment of atopic dermatitis. Journal of Dermatological Treatment 2020;31:33-40. [DOI: 10.1080/09546634.2019.1577549] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
139 Selmi C, Generali E, Massarotti M, Bianchi G, Sciré CA. New treatments for inflammatory rheumatic disease. Immunol Res 2014;60:277-88. [PMID: 25381481 DOI: 10.1007/s12026-014-8565-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 4.7] [Reference Citation Analysis]
140 Tanaka Y, Atsumi T, Amano K, Harigai M, Ishii T, Kawaguchi O, Rooney TP, Akashi N, Takeuchi T. Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials. Mod Rheumatol 2018;28:583-91. [PMID: 29134891 DOI: 10.1080/14397595.2017.1392057] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
141 Iancovici L, Khateeb D, Harel O, Peri R, Slobodin G, Hazan Y, Melamed D, Kessel A, Bar-On Y. Rheumatoid arthritis patients treated with Janus kinase inhibitors show reduced humoral immune responses following BNT162b2 vaccination. Rheumatology (Oxford) 2021:keab879. [PMID: 34849628 DOI: 10.1093/rheumatology/keab879] [Reference Citation Analysis]
142 Tanaka Y. Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview. J Clin Med 2021;10:1241. [PMID: 33802804 DOI: 10.3390/jcm10061241] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
143 Mooney L, Goodyear CS, Chandra T, Kirschner K, Copland M, Petrie MC, Lang NN. Clonal haematopoiesis of indeterminate potential: intersections between inflammation, vascular disease and heart failure. Clin Sci (Lond) 2021;135:991-1007. [PMID: 33861346 DOI: 10.1042/CS20200306] [Reference Citation Analysis]
144 Takeuchi T, Tanaka Y, Rokuda M, Izutsu H, Kaneko Y, Fukuda M, Kato D. A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years. Mod Rheumatol 2021;31:543-55. [PMID: 33050760 DOI: 10.1080/14397595.2020.1836789] [Reference Citation Analysis]
145 Miyatake D, Shibata T, Shibata M, Kaneko Y, Oda K, Nishimura T, Katashima M, Sekino H, Furihata K, Urae A. Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects with Normal and Impaired Renal Function. Clin Drug Investig 2020;40:149-59. [PMID: 31729626 DOI: 10.1007/s40261-019-00873-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
146 Salaffi F, Carotti M, Farah S, Ceccarelli L, Giovagnoni A, Di Carlo M. Early response to JAK inhibitors on central sensitization and pain catastrophizing in patients with active rheumatoid arthritis. Inflammopharmacology 2022. [PMID: 35505266 DOI: 10.1007/s10787-022-00995-z] [Reference Citation Analysis]
147 Huang Q, Han L, Lv R, Ling L. Magnolol exerts anti-asthmatic effects by regulating Janus kinase-signal transduction and activation of transcription and Notch signaling pathways and modulating Th1/Th2/Th17 cytokines in ovalbumin-sensitized asthmatic mice. Korean J Physiol Pharmacol 2019;23:251-61. [PMID: 31297009 DOI: 10.4196/kjpp.2019.23.4.251] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
148 Aittomäki S, Pesu M. Therapeutic targeting of the Jak/STAT pathway. Basic Clin Pharmacol Toxicol 2014;114:18-23. [PMID: 24164900 DOI: 10.1111/bcpt.12164] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 7.6] [Reference Citation Analysis]
149 Nørgård BM, Nielsen J, Knudsen T, Nielsen RG, Larsen MD, Jølving LR, Kjeldsen J. Hospitalization for COVID-19 in patients treated with selected immunosuppressant and immunomodulating agents, compared to the general population: A Danish cohort study. Br J Clin Pharmacol 2021;87:2111-20. [PMID: 33098713 DOI: 10.1111/bcp.14622] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
150 Gehringer M, Forster M, Pfaffenrot E, Bauer SM, Laufer SA. Novel hinge-binding motifs for Janus kinase 3 inhibitors: a comprehensive structure-activity relationship study on tofacitinib bioisosteres. ChemMedChem 2014;9:2516-27. [PMID: 25139757 DOI: 10.1002/cmdc.201402252] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
151 Apel F, Andreeva L, Knackstedt LS, Streeck R, Frese CK, Goosmann C, Hopfner KP, Zychlinsky A. The cytosolic DNA sensor cGAS recognizes neutrophil extracellular traps. Sci Signal 2021;14:eaax7942. [PMID: 33688080 DOI: 10.1126/scisignal.aax7942] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
152 Namour F, Diderichsen PM, Cox E, Vayssière B, Van der Aa A, Tasset C, Van't Klooster G. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection. Clin Pharmacokinet 2015;54:859-74. [PMID: 25681059 DOI: 10.1007/s40262-015-0240-z] [Cited by in Crossref: 81] [Cited by in F6Publishing: 74] [Article Influence: 13.5] [Reference Citation Analysis]
153 González-gay MA, Pina T, Prieto-peña D, Calderon-goercke M, Blanco R, Castañeda S. Drug therapies for polymyalgia rheumatica: a pharmacotherapeutic update. Expert Opinion on Pharmacotherapy 2018;19:1235-44. [DOI: 10.1080/14656566.2018.1501360] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
154 Edwards CJ, Sawant R, Garg V, Du EX, Friedman A, Betts KA. A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis. Rheumatol Ther 2021;8:167-81. [PMID: 33244703 DOI: 10.1007/s40744-020-00257-w] [Reference Citation Analysis]
155 Huang F, Luo Z. Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials. Clin Rheumatol 2019;38:523-34. [DOI: 10.1007/s10067-018-4299-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
156 Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, King BA, Thyssen JP, Silverberg JI, Bieber T, Kabashima K, Tsunemi Y, Costanzo A, Guttman-Yassky E, Beck LA, Janes JM, DeLozier AM, Gamalo M, Brinker DR, Cardillo T, Nunes FP, Paller AS, Wollenberg A, Reich K. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 2020;183:242-55. [PMID: 31995838 DOI: 10.1111/bjd.18898] [Cited by in Crossref: 75] [Cited by in F6Publishing: 74] [Article Influence: 37.5] [Reference Citation Analysis]
157 Gadina M. Advances in kinase inhibition: treating rheumatic diseases and beyond. Curr Opin Rheumatol 2014;26:237-43. [PMID: 24419749 DOI: 10.1097/BOR.0000000000000023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
158 Fragoulis GE, Brock J, Basu N, McInnes IB, Siebert S. The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions. J Allergy Clin Immunol 2021;148:941-52. [PMID: 34450118 DOI: 10.1016/j.jaci.2021.08.010] [Reference Citation Analysis]
159 Wells AF, Greenwald M, Bradley JD, Alam J, Arora V, Kartman CE. Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis. Rheumatol Ther 2018;5:43-55. [PMID: 29680881 DOI: 10.1007/s40744-018-0110-x] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
160 Coskun M, Salem M, Pedersen J, Nielsen OH. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res. 2013;76:1-8. [PMID: 23827161 DOI: 10.1016/j.phrs.2013.06.007] [Cited by in Crossref: 160] [Cited by in F6Publishing: 154] [Article Influence: 17.8] [Reference Citation Analysis]
161 Nielsen MA, Lomholt S, Mellemkjaer A, Andersen MN, Buckley CD, Kragstrup TW. Responses to Cytokine Inhibitors Associated with Cellular Composition in Models of Immune-Mediated Inflammatory Arthritis. ACR Open Rheumatol 2020;2:3-10. [PMID: 31943973 DOI: 10.1002/acr2.11094] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
162 Genovese MC, Greenwald MW, Gutierrez-Ureña SR, Cardiel MH, Poiley JE, Zubrzycka-Sienkiewicz A, Codding CE, Wang A, He W, Amos R, Vinueza R, Wang X, Garg JP, Kivitz AJ. Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study. Rheumatol Ther 2019;6:503-20. [PMID: 31410787 DOI: 10.1007/s40744-019-00167-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
163 Takahashi Y, Byrareddy SN, Albrecht C, Brameier M, Walter L, Mayne AE, Dunbar P, Russo R, Little DM, Villinger T, Khowawisetsut L, Pattanapanyasat K, Villinger F, Ansari AA. In vivo administration of a JAK3 inhibitor during acute SIV infection leads to significant increases in viral load during chronic infection. PLoS Pathog 2014;10:e1003929. [PMID: 24603870 DOI: 10.1371/journal.ppat.1003929] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
164 Williams JJL, Alotaiq N, Mullen W, Burchmore R, Liu L, Baillie GS, Schaper F, Pilch PF, Palmer TM. Interaction of suppressor of cytokine signalling 3 with cavin-1 links SOCS3 function and cavin-1 stability. Nat Commun 2018;9:168. [PMID: 29330478 DOI: 10.1038/s41467-017-02585-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
165 Lee KY, Yoo BW, Ahn SS, Bae WH, Lee H, Jung SM, Lee SW, Park YB, Song JJ. Predictors of mortality in autoimmune disease patients with concurrent cytomegalovirus infections detected by quantitative real-time PCR. PLoS One 2017;12:e0181590. [PMID: 28742877 DOI: 10.1371/journal.pone.0181590] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
166 Wang EA, Suzuki E, Maverakis E, Adamopoulos IE. Targeting IL-17 in psoriatic arthritis. Eur J Rheumatol 2017;4:272-7. [PMID: 29308283 DOI: 10.5152/eurjrheum.2017.17037] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
167 Tagami M, Honda S, Azumi A. Insights into Current Management Strategies for Dysthyroid Optic Neuropathy: A Review. OPTH 2022;Volume 16:841-50. [DOI: 10.2147/opth.s284609] [Reference Citation Analysis]
168 Ma Y, Meng J, Jia J, Wang M, Teng J, Zhu D, Yang C, Hu Q. Current and emerging biological therapy in adult-onset Still's disease. Rheumatology (Oxford) 2021;60:3986-4000. [PMID: 34117886 DOI: 10.1093/rheumatology/keab485] [Reference Citation Analysis]
169 Tanaka Y. Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs. Rheumatology (Oxford) 2021;60:vi12-20. [PMID: 34951925 DOI: 10.1093/rheumatology/keab609] [Reference Citation Analysis]
170 Saalfeld W, Mixon AM, Zelie J, Lydon EJ. Differentiating Psoriatic Arthritis from Osteoarthritis and Rheumatoid Arthritis: A Narrative Review and Guide for Advanced Practice Providers. Rheumatol Ther 2021;8:1493-517. [PMID: 34519965 DOI: 10.1007/s40744-021-00365-1] [Reference Citation Analysis]
171 Chen H, Li M, Ng N, Yu E, Bujarski S, Yin Z, Wen M, Hekmati T, Field D, Wang J, Nassir I, Yu J, Huang J, Daniely D, Wang CS, Xu N, Spektor TM, Berenson JR. Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma. Br J Haematol 2021;192:568-76. [PMID: 33341940 DOI: 10.1111/bjh.17282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
172 Endo W, Arito M, Sato T, Kurokawa MS, Omoteyama K, Iizuka N, Okamoto K, Suematsu N, Nakamura H, Beppu M, Kato T. Effects of sulfasalazine and tofacitinib on the protein profile of articular chondrocytes. Modern Rheumatology 2013;24:844-50. [DOI: 10.3109/14397595.2013.864225] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
173 McInnes IB, Szekanecz Z, McGonagle D, Maksymowych WP, Pfeil A, Lippe R, Song IH, Lertratanakul A, Sornasse T, Biljan A, Deodhar A. A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition. Rheumatology (Oxford) 2021:keab740. [PMID: 34668515 DOI: 10.1093/rheumatology/keab740] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
174 Stalder R, Zhang B, Jean Wrobel L, Boehncke W, Brembilla NC. The Janus Kinase inhibitor tofacitinib impacts human dendritic cell differentiation and favours M1 macrophage development. Exp Dermatol 2019;29:71-8. [DOI: 10.1111/exd.14059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
175 Blüml S, Redlich K, Smolen JS. Mechanisms of tissue damage in arthritis. Semin Immunopathol 2014;36:531-40. [PMID: 25212687 DOI: 10.1007/s00281-014-0442-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
176 Limen RY, Sedono R, Sugiarto A, Hariyanto TI. Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis. Expert Rev Anti Infect Ther 2021;:1-10. [PMID: 34538216 DOI: 10.1080/14787210.2021.1982695] [Reference Citation Analysis]
177 Boland BS, Vermeire S. Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease. Gastroenterol Clin North Am 2017;46:627-44. [PMID: 28838419 DOI: 10.1016/j.gtc.2017.05.015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
178 Schmieder G, Draelos Z, Pariser D, Banfield C, Cox L, Hodge M, Kieras E, Parsons-rich D, Menon S, Salganik M, Page K, Peeva E. Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study. Br J Dermatol 2018;179:54-62. [DOI: 10.1111/bjd.16004] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 8.8] [Reference Citation Analysis]
179 Bryan MC, Rajapaksa NS. Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances. J Med Chem 2018;61:9030-58. [DOI: 10.1021/acs.jmedchem.8b00667] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
180 Rossi A, Muscianese M, Piraccini BM, Starace M, Carlesimo M, Mandel VD, Alessandrini A, Calvieri S, Caro G, D'arino A, Federico A, Magri F, Pigliacelli F, Amendolagine G, Annunziata MC, Arisi MC, Astorino S, Babino G, Bardazzi F, Barruscotti S, Belloni Fortina A, Borghi A, Bruni F, Caccavale S, Calzavara-Pinton P, Cameli N, Cardone M, Carugno A, Coppola R, Dattola A, De Felici Del Giudice MB, Di Cesare A, Dika E, Di Nunno D, D'ovidio R, Fabbrocini G, Feliciani C, Fulgione E, Galluzzo M, Garcovich S, Garelli V, Guerriero C, Hansel K, La Placa M, Lacarrubba F, Lora V, Marinello E, Megna M, Micali G, Misciali C, Monari P, Monfrecola G, Neri I, Offidani A, Orlando G, Papini M, Patrizi A, Piaserico S, Rivetti N, Simonetti O, Stan TR, Stingeni L, Talamonti M, Tassone F, Villa L, Vincenzi C, Fortuna MC. Italian Guidelines in diagnosis and treatment of alopecia areata. G Ital Dermatol Venereol 2019;154:609-23. [PMID: 31578836 DOI: 10.23736/S0392-0488.19.06458-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
181 Jamilloux Y, El Jammal T, Vuitton L, Gerfaud-Valentin M, Kerever S, Sève P. JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun Rev 2019;18:102390. [PMID: 31520803 DOI: 10.1016/j.autrev.2019.102390] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 26.7] [Reference Citation Analysis]
182 Bui VL, Brahn E. Cytokine targeting in rheumatoid arthritis. Clin Immunol 2019;206:3-8. [PMID: 29621613 DOI: 10.1016/j.clim.2018.04.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
183 Goswami R, Kaplan M. STAT Transcription Factors in T Cell Control of Health and Disease. Elsevier; 2017. pp. 123-80. [DOI: 10.1016/bs.ircmb.2016.09.012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
184 Nosadini M, Sartori S, Sharma S, Dale RC. Immunotherapeutics in Pediatric Autoimmune Central Nervous System Disease: Agents and Mechanisms. Seminars in Pediatric Neurology 2017;24:214-28. [DOI: 10.1016/j.spen.2017.08.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
185 Kitanaga Y, Imamura E, Nakahara Y, Fukahori H, Fujii Y, Kubo S, Nakayamada S, Tanaka Y. In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors. Rheumatology (Oxford) 2020;59:1957-68. [PMID: 31764973 DOI: 10.1093/rheumatology/kez526] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
186 Su D, Gao YQ, Deng YJ, Zhang HH, Wu YR, Hu Y, Mei QX. Identification of Chinese Herbal Compounds with Potential as JAK3 Inhibitors. Evid Based Complement Alternat Med 2019;2019:4982062. [PMID: 31093295 DOI: 10.1155/2019/4982062] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
187 Dagnew AF, Rausch D, Hervé C, Zahaf T, Levin MJ, Schuind A; ZOE-50/70 study group. Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials. Rheumatology (Oxford) 2021;60:1226-33. [PMID: 32910152 DOI: 10.1093/rheumatology/keaa424] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
188 Delgado-Ramirez Y, Colly V, Gonzalez GV, Leon-Cabrera S. Signal transducer and activator of transcription 6 as a target in colon cancer therapy. Oncol Lett 2020;20:455-64. [PMID: 32565970 DOI: 10.3892/ol.2020.11614] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
189 Arnaldez FI, O'Day SJ, Drake CG, Fox BA, Fu B, Urba WJ, Montesarchio V, Weber JS, Wei H, Wigginton JM, Ascierto PA. The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response. J Immunother Cancer. 2020;8:e000930. [PMID: 32385146 DOI: 10.1136/jitc-2020-000930] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 22.0] [Reference Citation Analysis]
190 Connell SJ, Jabbari A. The current state of knowledge of the immune ecosystem in alopecia areata. Autoimmunity Reviews 2022. [DOI: 10.1016/j.autrev.2022.103061] [Reference Citation Analysis]
191 Malik K, Guttman-yassky E. Cytokine Targeted Therapeutics for Alopecia Areata: Lessons from Atopic Dermatitis and Other Inflammatory Skin Diseases. Journal of Investigative Dermatology Symposium Proceedings 2018;19:S62-4. [DOI: 10.1016/j.jisp.2017.10.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
192 Yamaoka K. Janus kinase inhibitors for rheumatoid arthritis. Curr Opin Chem Biol 2016;32:29-33. [PMID: 26994322 DOI: 10.1016/j.cbpa.2016.03.006] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 13.7] [Reference Citation Analysis]
193 Reynolds G, Cooles FA, Isaacs JD, Hilkens CM. Emerging immunotherapies for rheumatoid arthritis. Hum Vaccin Immunother 2014;10:822-37. [PMID: 24535556 DOI: 10.4161/hv.27910] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
194 Boland BS, Sandborn WJ, Chang JT. Update on Janus kinase antagonists in inflammatory bowel disease. Gastroenterol Clin North Am. 2014;43:603-617. [PMID: 25110261 DOI: 10.1016/j.gtc.2014.05.011] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
195 Keystone EC, Genovese MC, Schlichting DE, de la Torre I, Beattie SD, Rooney TP, Taylor PC. Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis. J Rheumatol 2018;45:14-21. [DOI: 10.3899/jrheum.161161] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 7.4] [Reference Citation Analysis]
196 Li R, Hadi S, Guttman-yassky E. Current and emerging biologic and small molecule therapies for atopic dermatitis. Expert Opinion on Biological Therapy 2019;19:367-80. [DOI: 10.1080/14712598.2019.1573422] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
197 Daoud S, Taha MO. Pharmacophore modeling of JAK1: A target infested with activity-cliffs. J Mol Graph Model 2020;99:107615. [PMID: 32339898 DOI: 10.1016/j.jmgm.2020.107615] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
198 Pourang A, Mesinkovska NA. New and Emerging Therapies for Alopecia Areata. Drugs 2020;80:635-46. [PMID: 32323220 DOI: 10.1007/s40265-020-01293-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
199 George G, Shyni GL, Raghu KG. Current and novel therapeutic targets in the treatment of rheumatoid arthritis. Inflammopharmacology 2020;28:1457-76. [PMID: 32948901 DOI: 10.1007/s10787-020-00757-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
200 Meephansan J, Thummakriengkrai J, Ponnikorn S, Yingmema W, Deenonpoe R, Suchonwanit P. Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia: possible mechanism via VEGF induction. Arch Dermatol Res 2017;309:729-38. [DOI: 10.1007/s00403-017-1777-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
201 Senkevitch E, Durum S. The promise of Janus kinase inhibitors in the treatment of hematological malignancies. Cytokine 2017;98:33-41. [PMID: 28277287 DOI: 10.1016/j.cyto.2016.10.012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
202 Qin J, Shen X, Zhang J, Jia D. Allosteric inhibitors of the STAT3 signaling pathway. European Journal of Medicinal Chemistry 2020;190:112122. [DOI: 10.1016/j.ejmech.2020.112122] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
203 Egwuagu CE, Alhakeem SA, Mbanefo EC. Uveitis: Molecular Pathogenesis and Emerging Therapies. Front Immunol 2021;12:623725. [PMID: 33995347 DOI: 10.3389/fimmu.2021.623725] [Reference Citation Analysis]
204 Eisman S, Sinclair R. Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata. Expert Opin Investig Drugs 2021;:1-6. [PMID: 34826225 DOI: 10.1080/13543784.2021.2012149] [Reference Citation Analysis]
205 Wang W, Xu L, Su J, Peppelenbosch MP, Pan Q. Transcriptional Regulation of Antiviral Interferon-Stimulated Genes. Trends Microbiol 2017;25:573-84. [PMID: 28139375 DOI: 10.1016/j.tim.2017.01.001] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 13.8] [Reference Citation Analysis]
206 Tanaka Y. The JAK inhibitors: do they bring a paradigm shift for the management of rheumatic diseases? Rheumatology (Oxford) 2019;58:i1-3. [PMID: 30806705 DOI: 10.1093/rheumatology/key280] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
207 You Z, Timilshina M, Jeong BS, Chang JH. BJ-2266 ameliorates experimental autoimmune encephalomyelitis through down-regulation of the JAK/STAT signaling pathway. Eur J Immunol 2017;47:1488-500. [PMID: 28681958 DOI: 10.1002/eji.201646860] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
208 McGuire VA, Ruiz-Zorrilla Diez T, Emmerich CH, Strickson S, Ritorto MS, Sutavani RV, Weiβ A, Houslay KF, Knebel A, Meakin PJ, Phair IR, Ashford ML, Trost M, Arthur JS. Dimethyl fumarate blocks pro-inflammatory cytokine production via inhibition of TLR induced M1 and K63 ubiquitin chain formation. Sci Rep 2016;6:31159. [PMID: 27498693 DOI: 10.1038/srep31159] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 8.8] [Reference Citation Analysis]
209 Gurzov EN, Stanley WJ, Pappas EG, Thomas HE, Gough DJ. The JAK/STAT pathway in obesity and diabetes. FEBS J. 2016;283:3002-3015. [PMID: 26972840 DOI: 10.1111/febs.13709] [Cited by in Crossref: 79] [Cited by in F6Publishing: 77] [Article Influence: 13.2] [Reference Citation Analysis]
210 Coricello A, Mesiti F, Lupia A, Maruca A, Alcaro S. Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates. Molecules 2020;25:E3321. [PMID: 32707925 DOI: 10.3390/molecules25153321] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
211 Fautrel B, Kirkham B, Pope JE, Takeuchi T, Gaich C, Quebe A, Zhu B, de la Torre I, De Leonardis F, Taylor PC. Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM. J Clin Med 2019;8:E1394. [PMID: 31492040 DOI: 10.3390/jcm8091394] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
212 Bechman K, Subesinghe S, Norton S, Atzeni F, Galli M, Cope AP, Winthrop KL, Galloway JB. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford) 2019;58:1755-66. [PMID: 30982883 DOI: 10.1093/rheumatology/kez087] [Cited by in Crossref: 83] [Cited by in F6Publishing: 68] [Article Influence: 41.5] [Reference Citation Analysis]
213 Ross SH, Cantrell DA. Signaling and Function of Interleukin-2 in T Lymphocytes. Annu Rev Immunol 2018;36:411-33. [PMID: 29677473 DOI: 10.1146/annurev-immunol-042617-053352] [Cited by in Crossref: 167] [Cited by in F6Publishing: 163] [Article Influence: 55.7] [Reference Citation Analysis]
214 Norman P. Highly selective Janus kinase 3 inhibitors based on a pyrrolo[2,3- d ]pyrimidine scaffold: evaluation of WO2013085802. Expert Opinion on Therapeutic Patents 2013;24:121-5. [DOI: 10.1517/13543776.2014.851670] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
215 Hosseini A, Gharibi T, Marofi F, Javadian M, Babaloo Z, Baradaran B. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases. J Cell Physiol 2020;235:5903-24. [DOI: 10.1002/jcp.29593] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 12.5] [Reference Citation Analysis]
216 Gupta S, Cerosaletti K, Long SA. Renegade homeostatic cytokine responses in T1D: drivers of regulatory/effector T cell imbalance. Clin Immunol 2014;151:146-54. [PMID: 24576418 DOI: 10.1016/j.clim.2014.02.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
217 Wagner S, Lang S, Popp T, Schmidt A, Thiermann H, Steinritz D, Kehe K. Evaluation of selective and non-selective cyclooxygenase inhibitors on sulfur mustard-induced pro-inflammatory cytokine formation in normal human epidermal keratinocytes. Toxicology Letters 2019;312:109-17. [DOI: 10.1016/j.toxlet.2019.03.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
218 Kremer JM, Lawrence DA, Hamilton R, McInnes IB. Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures. RMD Open 2016;2:e000287. [PMID: 27335660 DOI: 10.1136/rmdopen-2016-000287] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
219 Schwartz DM, Bonelli M, Gadina M, O'Shea JJ. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12:25-36. [PMID: 26633291 DOI: 10.1038/nrrheum.2015.167] [Cited by in Crossref: 287] [Cited by in F6Publishing: 273] [Article Influence: 41.0] [Reference Citation Analysis]
220 Tanaka Y, Kavanaugh A, Wicklund J, McInnes IB. Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials. Mod Rheumatol 2021;:1-11. [PMID: 33740386 DOI: 10.1080/14397595.2021.1902617] [Reference Citation Analysis]
221 Toussirot E, Bonnefoy F, Vauchy C, Perruche S, Saas P. Mini-Review: The Administration of Apoptotic Cells for Treating Rheumatoid Arthritis: Current Knowledge and Clinical Perspectives. Front Immunol 2021;12:630170. [PMID: 33717160 DOI: 10.3389/fimmu.2021.630170] [Reference Citation Analysis]
222 Koride S, Nayak S, Banfield C, Peterson MC. Evaluating the Role of Janus Kinase Pathways in Platelet Homeostasis Using a Systems Modeling Approach. CPT Pharmacometrics Syst Pharmacol 2019;8:478-88. [PMID: 31044523 DOI: 10.1002/psp4.12419] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
223 Li J, Chen C, Wang J, Ye Z, Pan L, Liu Z, Tang C. Simultaneous measurement of upadacitinib and methotrexate by UPLC-MS/MS and its pharmacokinetic application in rats. J Chromatogr B Analyt Technol Biomed Life Sci 2021;1188:123071. [PMID: 34875493 DOI: 10.1016/j.jchromb.2021.123071] [Reference Citation Analysis]
224 Tanaka Y. Rheumatoid arthritis. Inflamm Regen 2020;40:20. [PMID: 32944095 DOI: 10.1186/s41232-020-00133-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
225 Gallo CG, Fiorino S, Posabella G, Antonacci D, Tropeano A, Pausini E, Pausini C, Guarniero T, Hong W, Giampieri E, Corazza I, Federico L, de Biase D, Zippi M, Zancanaro M. COVID-19, what could sepsis, severe acute pancreatitis, gender differences, and aging teach us? Cytokine 2021;148:155628. [PMID: 34411989 DOI: 10.1016/j.cyto.2021.155628] [Reference Citation Analysis]
226 Turk S, Merget B, Eid S, Fulle S. From Cancer to Pain Target by Automated Selectivity Inversion of a Clinical Candidate. J Med Chem 2018;61:4851-9. [PMID: 29746776 DOI: 10.1021/acs.jmedchem.8b00140] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]